# Assessing the Efficacy of Maxidex® and Patanol® for the Treatment of Allergic Conjunctivitis

> **NCT01119287** · PHASE4 · COMPLETED · sponsor: **Alcon Research** · enrollment: 180 (actual)

## Conditions studied

- Allergic Conjunctivitis

## Interventions

- **DRUG:** Dexamethasone 0.1% ophthalmic suspension
- **DRUG:** Olopatadine hydrochloride 0.1% ophthalmic solution
- **OTHER:** Inactive ingredients, used as placebo

## Key facts

- **NCT ID:** NCT01119287
- **Lead sponsor:** Alcon Research
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-03
- **Primary completion:** 2010-09
- **Final completion:** 2010-09
- **Target enrollment:** 180 (ACTUAL)
- **Last updated:** 2014-02-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01119287

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01119287, "Assessing the Efficacy of Maxidex® and Patanol® for the Treatment of Allergic Conjunctivitis". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT01119287. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*